Market Place
Sourcing Support
Genmab Announces DARZALEX Net Sales for Q1 2026
14 Apr 2026 //
GLOBENEWSWIRE
Genmab: Rina-S/Bevacizumab Safe in Advanced Ovarian Cancer
13 Apr 2026 //
PHARMIWEB
Genmab Announces Net Sales Of DARZALEX (Daratumumab) For 2025
21 Jan 2026 //
GLOBENEWSWIRE
Genmab Unveils Epcoritamab Phase 3 Results
16 Jan 2026 //
PHARMIWEB
Genmab Teams Up With Anthropic For AI-Powered R&D Acceleration
07 Jan 2026 //
BUSINESSWIRE
Genmab Scraps Development of Experimental Cancer Therapy
31 Dec 2025 //
REUTERS
Genmab Portfolio Prioritization Update
29 Dec 2025 //
BUSINESSWIRE
Genmab Announces Epcoritamab Data for Richter Transformation
08 Dec 2025 //
BUSINESSWIRE
Genmab Phase 3 EPCORE FL-1 Shows Benefit of EPKINLY Combo
07 Dec 2025 //
GLOBENEWSWIRE
Genmab Data Show Epcoritamab Remissions in DLBCL and FL Lymphoma
06 Dec 2025 //
BUSINESSWIRE
Genmab A/S Managers And Associates Engage In Share Transactions
20 Nov 2025 //
PHARMIWEB
Genmab Grants Restricted Stock Units And Warrants To Employees
20 Nov 2025 //
GLOBENEWSWIRE
Genmab Gets FDA Nod For Epkinly Combo In Follicular Lymphoma
18 Nov 2025 //
BUSINESSWIRE
Genmab Sees Capital Boost From Employee Warrant Exercise
18 Nov 2025 //
GLOBENEWSWIRE
Genmab Prices Notes Offering, Completes Loan Syndication
18 Nov 2025 //
GLOBENEWSWIRE
Genmab Sheds Another Clinical ADC From $1.8B Profoundbio Buy
17 Nov 2025 //
FIERCE BIOTECH
Genmab Presents Latest Blood Cancer Treatments at ASH 2025
03 Nov 2025 //
BUSINESSWIRE
Genmab Shows Rina-S Effectiveness In Advanced Endometrial Cancer
18 Oct 2025 //
GLOBENEWSWIRE
Genmab Reports Darzalex Net Sales in Q3 2025
14 Oct 2025 //
GLOBENEWSWIRE
Major Shareholder Announcement
23 Sep 2025 //
GLOBENEWSWIRE
Genmab Discards ADC from $1.8 B ProfoundBio Buy
17 Sep 2025 //
FIERCE BIOTECH
Genmab`s Capital Increase Due to Employee Warrant Exercise
09 Sep 2025 //
GLOBENEWSWIRE
Genmab A/S Share Transactions by Managerial Staff and Associates
09 Sep 2025 //
GLOBENEWSWIRE
Genmab Gets FDA Breakthrough Tag for Rina-S in Endometrial Cancer
26 Aug 2025 //
BUSINESSWIRE
Genmab to Join Morgan Stanley Global Healthcare Conference
26 Aug 2025 //
GLOBENEWSWIRE
Genmab Capital Increase Due to Employee Warrant Exercise
12 Aug 2025 //
GLOBENEWSWIRE
Genmab Ph3 EPCORE FL-1 Trial Meets Endpoints in Lymphoma Patients
08 Aug 2025 //
PHARMAWEB
Genmab Ph 3 EPCORE FL-1 Meets Endpoints in Follicular Lymphoma
07 Aug 2025 //
BUSINESSWIRE
Genmab Ph 3 EPCORE FL-1 Meets Dual Primary Endpoints in Lymphoma
07 Aug 2025 //
GLOBENEWSWIRE
Genmab Announces Financial Results for the First Half of 2025
07 Aug 2025 //
GLOBENEWSWIRE
Genmab Reports Q2 2025 Net Sales of DARZALEX® (daratumumab)
16 Jul 2025 //
GLOBENEWSWIRE
Genmab Announces Changes to its Executive Committee
01 Jul 2025 //
GLOBENEWSWIRE
Completion of Share Buy-back Program
30 Jun 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
23 Jun 2025 //
GLOBENEWSWIRE
Genmab`s Epcoritamab Combo Shows High Response in DLBCL
15 Jun 2025 //
BUSINESSWIRE
Genmab grants Restricted Stock Units and Warrants to Employees
12 Jun 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
10 Jun 2025 //
GLOBENEWSWIRE
Genmab`s Rin-S Shows Promise in Endometrial Cancer Trial
02 Jun 2025 //
BUSINESSWIRE
Genmab to Join Chat at 46th Goldman Sachs Health Conference
27 May 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
26 May 2025 //
GLOBENEWSWIRE
Endometrial Cancer Data on Genmab’s Elahere Rival Beat Forecast
23 May 2025 //
FIERCE BIOTECH
Genmab to Present Late-Stage Oncology Data at 2025 ASCO Meeting
22 May 2025 //
BUSINESSWIRE
Genmab Announces Financial Results for the First Quarter of 2024
08 May 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
05 May 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
28 Apr 2025 //
GLOBENEWSWIRE
Genmab reports Darzalex® Net Sales for Q1 2025
15 Apr 2025 //
GLOBENEWSWIRE
Transactions in Connection with Share Buy-back Program
14 Apr 2025 //
GLOBENEWSWIRE
Transactions In Connection with Share Buy-back Program
07 Apr 2025 //
GLOBENEWSWIRE
Genmab A/S Managerial Employees` Transactions with Shares
01 Apr 2025 //
GLOBENEWSWIRE
Transactions in connection with share buy-back program
31 Mar 2025 //
GLOBENEWSWIRE
TIVDAK® approved by European Commission for Cervical Cancer
31 Mar 2025 //
GLOBENEWSWIRE
Tivdak approved by Japan Ministry for Advanced Cervical Cancer
27 Mar 2025 //
BUSINESSWIRE
Genmab Announces Initiation of Share Buy-Back Program
25 Mar 2025 //
GLOBENEWSWIRE
Rinatabart Sesutecan Shows Antitumor Activity in Ovarian Cancer
17 Mar 2025 //
GLOBENEWSWIRE
Rina-S: Shows Encouraging Antitumor Activity In Advanced Ovarian Cancer
17 Mar 2025 //
BUSINESSWIRE
Passing of Genmab A/S Annual General Meeting
12 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S Board Grants Restricted Stock Units and Warrants
12 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S managerial employees and associates` share transaction
12 Mar 2025 //
GLOBENEWSWIRE
Genmab announces Johnson & Johnson decision on HexaBody-CD38
10 Mar 2025 //
GLOBENEWSWIRE
Genmab A/S managerial employees and associates` share transaction
04 Mar 2025 //
GLOBENEWSWIRE
